NCT04390399: An ongoing trial by ImmunityBio, Inc.
This trial is ongoing. It must report results 10 months, 2 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04390399 |
|---|---|
| Title | Open-label, Randomized, Comparative Phase 2 Study of Combination Immunotherapy Plus Standard-of-care Chemotherapy Versus Standard-of-care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 21, 2020 |
| Completion date | Oct. 31, 2025 |
| Required reporting date | Oct. 31, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |